DeepMed Research

Daewon Pharmaceutical Co., Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1958-01-07

Employees: 1.2K

Market Cap: -

Website: http://www.daewonpharm.com

Clinical Trials

Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R

Phase 1

Completed

Conditions: Apetite Stimulants

Interventions: Drug: DW5221
Drug: DW5221-R

First Posted Date: 2023-11-28

Last Posted Date: 2023-11-28

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 54

Registration Number: NCT06147908

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

Phase 3

Completed

Conditions: Hypercholesterolemia, Dyslipidemia

Interventions: Drug: Ezetimibe 10mg
Drug: Atorvastatin 10mg
Drug: Ezetimibe/Atorvastatin 10/5 mg
Drug: Atorvastatin 5mg
Drug: DW1125 placebo
Drug: DW1125E placebo
Drug: DW1125A placebo
Drug: DW1125A-1 placebo

First Posted Date: 2023-08-01

Last Posted Date: 2023-08-01

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 252

Registration Number: NCT05970679

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of DWKH

Phase 3

Completed

Conditions: Respiratory Infection

Interventions: Drug: DWKH
Drug: DWKH-R
Drug: Placebo

First Posted Date: 2023-01-13

Last Posted Date: 2023-01-13

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 186

Registration Number: NCT05683951

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2

Phase 1

Completed

Conditions: Rheumatoid Arthritis
Back Pain
Osteoarthritis
Acute Upper Respiratory Tract Infection

Interventions: Drug: DW1809-T2
Drug: DW1809-1

First Posted Date: 2022-01-31

Last Posted Date: 2022-01-31

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 37

Registration Number: NCT05214690

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809

Phase 1

Completed

Conditions: Osteoarthritis
Rheumatoid Arthritis
Back Pain
Acute Upper Respiratory Tract Infection

Interventions: Drug: DW1809
Drug: DW1809-1

First Posted Date: 2022-01-31

Last Posted Date: 2022-01-31

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 38

Registration Number: NCT05214677

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of

To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient

Phase 3

Completed

Conditions: Gastritis Acute
Gastritis Chronic

Interventions: Drug: DW1903-R1
Drug: DW1903

First Posted Date: 2021-12-20

Last Posted Date: 2021-12-20

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 332

Registration Number: NCT05163756

Locations: 🇰🇷
Korea University Ansan Hospital, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of DW1903

Phase 1

Completed

Conditions: Gastritis

Interventions: Drug: DW1903
Drug: DW1903-R1
Drug: DW1903-R2

First Posted Date: 2021-12-13

Last Posted Date: 2021-12-13

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 31

Registration Number: NCT05155072

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of

Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea

Phase 3

Conditions: Primary Dysmenorrhea

Interventions: Drug: Pelubiprofen 45mg
Drug: Placebo

First Posted Date: 2020-09-09

Last Posted Date: 2020-09-09

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT04541134

Clinical Trial to Evaluate the Efficacy and Safety of 'DW1601' in Acute Bronchitis

Phase 3

Conditions: Acute Bronchitis

Interventions: Drug: DW16012
Drug: DW16011
Drug: DW1601

First Posted Date: 2020-02-07

Last Posted Date: 2020-02-07

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 204

Registration Number: NCT04260555

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of 'Pelubiprofen Controlled Released Tab.' in Acute Traumatic Injury

Phase 3

Conditions: Acute Traumatic Injury

Interventions: Drug: pelubiprofen 45mg
Drug: pelubiprofen placebo

First Posted Date: 2019-03-14

Last Posted Date: 2019-03-19

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 94

Registration Number: NCT03874247

Locations: 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy